Disease · MONDO_0000313

hypophosphatemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hypophosphatemia. Diseases, record MONDO_0000313. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000313

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hypophosphatemia; Open Targets
Open Targets ID: MONDO_0000313; Open Targets
Other names: Decreased phosphate ion concentration, Decreased phosphate ion level, Decreased phosphate ion level in blood, Hypophosphataemia, Low blood phosphate level, Reduced phosphate ion concentration, Reduced phosphate ion level, Reduced phosphate ion level in blood, hypophosphatemia (disease); Open Targets
Disease Ontology: DOID:0050336; Disease Ontology
MeSH: D017674; MeSH
NCI Thesaurus: C37977; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 10 drugs, from DailyMed, FDA and PMDA; Open Targets

Drugs10

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BUROSUMAB	CHEMBL3707326	Antibody	Approval	DailyMed and FDA	4	2	2	Drugs and targets
POTASSIUM PHOSPHATE, MONOBASIC	CHEMBL1200925	Small molecule	Approval	DailyMed	3	1	1	Drugs and targets
ERGOCALCIFEROL	CHEMBL1536	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	CHEMBL1060	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
FERRIC CARBOXYMALTOSE	CHEMBL2108597		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
FERRIC DERISOMALTOSE	CHEMBL4298187	Oligosaccharide	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
IRON ISOMALTOSIDE 1000	CHEMBL4298046		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM GLYCEROPHOSPHATE	CHEMBL6067979		Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
CINACALCET	CHEMBL1201284	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM PHOSPHATE, MONOBASIC	CHEMBL1368	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets3

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CASR	Extracellular calcium-sensing receptor	1	Calcium sensing receptor positive allosteric modulator	Unknown	https://conductscience.org/library/genes/846	Drugs and targets
FGF23	Fibroblast growth factor 23	1	Fibroblast growth factor 23 inhibitor	Approval	https://conductscience.org/library/genes/8074	Drugs and targets
VDR	Vitamin D3 receptor	1	Vitamin D receptor agonist	Approval	https://conductscience.org/library/genes/7421	Drugs and targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02526160	Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)	Phase 3	134	2021-02-05	X-linked Hypophosphatemia	BUROSUMAB	Its record names the disease	ClinicalTrials.gov
NCT03237065	Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia	Phase 3	122	2020-02-25	Iron Deficiency Anaemia, Iron Deficiency Anemia	FERRIC CARBOXYMALTOSE, FERRIC DERISOMALTOSE, IRON ISOMALTOSIDE 1000	Its record names the disease	ClinicalTrials.gov
NCT05509595	Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia	Phase 2	12	2026-02-02	Fibrous Dysplasia Of Bone	BUROSUMAB	Its record names the disease	ClinicalTrials.gov
NCT07233889	Enteral Supplementation With Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules for the Treatment of Hypophosphatemia.	Not applicable	60		Hypophosphatemia	SODIUM PHOSPHATE, MONOBASIC	Its record names the disease	ClinicalTrials.gov
NCT06651892	The Efficacy and Safety of Diluted Oral Phosphate Enema Versus Intravenous Sodium Glycerophosphate in The Treatment of Hypophosphatemia in ICU Patients	Phase 2/3	42		Acute Hypophosphatemia	SODIUM GLYCEROPHOSPHATE	Its record names the disease	ClinicalTrials.gov
NCT01011114	Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant	Not applicable	40		Hypophosphatemia, Renal Transplant	CINACALCET	Its record names the disease	ClinicalTrials.gov
NCT01676844	Investigating a New Way of Giving Medicine to Newborn and Preterm Babies	Phase 2	20		Hypophosphataemia, Osteopenia of Prematurity	POTASSIUM PHOSPHATE, MONOBASIC	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose: Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions	0 of 62	2 of 57	119	NCT03237065	Trial comparisons
Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose: Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL)	5 of 62	42 of 57	119	NCT03237065	Trial comparisons
Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose: deaths from any cause	0 of 62	0 of 57	119	NCT03237065	Trial comparisons
Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose: serious adverse events	0 of 62	1 of 57	119	NCT03237065	Trial comparisons
Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose: Incidence of S-phosphate Level ≤1.0 mg/dL at Any Time From Baseline to Day 35	0 of 61	6 of 56	117	NCT03237065	Trial comparisons
Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose: Proportion of Subjects With Hypophosphatemia on Day 35 (S-phosphate Level <2.0 mg/dL)	0 of 58	25 of 56	114	NCT03237065	Trial comparisons

Papers from its trials20

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38537225	RESULT	1	PubMed
37042685	RESULT	1	PubMed
36065653	RESULT	1	PubMed
35511366	RESULT	1	PubMed
34705137	RESULT	1	PubMed
31165191	RESULT	1	PubMed
30569887	RESULT	1	PubMed
29947083	RESULT	1	PubMed
22863286	RESULT	1	PubMed
20682049	RESULT	1	PubMed

1 to 10 of 20

See all 20 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000313

GET https://conductscience.org/api/diseases/v1/MONDO_0000313/drugs

API reference For AI assistants